Benitec Biopharma (BNTC) Stock Price, News & Analysis

Company Overview

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions. The hepatitis B program is advancing through preclinical studies to demonstrate potent and durable suppression of viral replication. In ocular disease, the company is exploring local delivery approaches to address wet age-related macular degeneration and other retinal disorders with RNAi-based constructs.

Founded and headquartered in Australia, Benitec maintains research operations in both Melbourne and San Diego, California. Its international footprint supports collaboration with academic centers and contract development organizations to accelerate preclinical evaluation and future clinical trials. The company holds a portfolio of intellectual property covering its ddRNAi technology and related gene-silencing applications.

Led by a management team with experience in gene therapy, molecular biology and drug development, Benitec Biopharma is focused on translating its platform into clinical-stage assets. The company continues to explore partnerships and licensing opportunities to broaden the scope of its gene-silencing pipeline and advance novel treatments toward regulatory approval.

Key Stats

• Today's Range: $12.76 to $13.35
• 50-Day Range: $11.44 to $13.78
• 52-Week Range: $9.85 to $16.76
• Volume: 254,950 shs
• Average Volume: 177,692 shs
• Market Capitalization: $447.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.80
• Consensus Rating: Moderate Buy

Benitec Biopharma Stock Analysis - MarketRank™

Benitec Biopharma scored higher than 48% of companies evaluated by MarketBeat, and ranked 557th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Benitec Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Benitec Biopharma has a consensus price target of $24.80, representing about 90.5% upside from its current price of $13.02.

Amount of Analyst Coverage

Benitec Biopharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Benitec Biopharma are expected to decrease in the coming year, from ($1.02) to ($1.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Benitec Biopharma is -11.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Benitec Biopharma is -11.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Benitec Biopharma has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.44% of the float of Benitec Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Benitec Biopharma has a short interest ratio ("days to cover") of 9.94.

Change versus previous month

Short interest in Benitec Biopharma has recently decreased by 1.83%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Benitec Biopharma does not currently pay a dividend.

Dividend Growth

Benitec Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.35

News Sentiment

Benitec Biopharma has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Benitec Biopharma this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for BNTC on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Benitec Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.80% of the stock of Benitec Biopharma is held by insiders.

Percentage Held by Institutions

52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 8/26/2026
• Next Earnings (Estimated): 9/28/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BNTC
• CIK: 1808898
• Web: www.benitec.com
• Phone: 510-780-0819
• Fax: 61 (0)3 9966-9923
• Employees: 20
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Benitec Biopharma: $24.80
• High Price Target: $32.00
• Low Price Target: $16.00
• Potential Upside/Downside: +90.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.92 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -34.82%
• Return on Assets: -34.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 56.82
• Quick Ratio: 56.82

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.71 per share
• Price / Book: 3.51

Miscellaneous

• Outstanding Shares: 34,350,000
• Free Float: 32,705,000
• Market Cap: $447.24 million
• Optionable: No Data
• Beta: 0.28